Is ImClone Out of the Woods?
Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
← What's in a Drug Name? (previous entry)
(next entry) What To Expect From A Venture Capitalist →
© Copyright - BiotechBlog — A thinkBiotech product
Leave a Reply
Want to join the discussion?Feel free to contribute!